Invasive candidiasis (IC) remains a significant public health issue, with increasing incidence and mortality rates. The disease is caused by various Candida species, with Candida albicans being the most common, although other species such as C. glabrata, C. parapsilosis, and C. tropicalis are also prevalent. IC is often associated with immunocompromised patients, those with underlying diseases, and those receiving broad-spectrum antibiotics or other immunosuppressive therapies. The burden of IC is substantial, with an estimated 63,000 infections per year in the United States, and a high mortality rate, particularly in cases of candidemia. The mortality rate for IC has remained relatively stable over the past decade, while that for invasive aspergillosis (IA) has shown a decline. Population-based surveillance studies have shown that IC is more common than other invasive fungal infections, with a high incidence in certain populations, including neonates, cancer patients, and those with diabetes. The species distribution of Candida isolates varies geographically and temporally, with C. glabrata becoming more prevalent in some regions. Antifungal susceptibility testing has revealed that some species, such as C. glabrata and C. krusei, are increasingly resistant to common antifungal agents like fluconazole. This resistance is a growing concern, as it may limit treatment options and increase mortality. The use of standardized antifungal susceptibility testing methods has improved the ability to monitor resistance patterns and guide treatment decisions. Amphotericin B remains a critical antifungal agent, although resistance to it is becoming more common in certain species. The development of resistance to amphotericin B is a significant challenge, particularly in cases involving C. glabrata. Other antifungal agents, such as triazoles, echinocandins, and 5FC, are also being used more frequently, with varying degrees of effectiveness against different Candida species. Prevention strategies, including infection control measures and prophylactic antifungal therapy, are essential in reducing the incidence and mortality of IC. The management of IC requires a multidisciplinary approach, with a focus on early diagnosis, appropriate antifungal therapy, and prevention of hospital-acquired infections. Continued research and surveillance are needed to better understand the epidemiology of IC and to develop more effective treatment strategies.Invasive candidiasis (IC) remains a significant public health issue, with increasing incidence and mortality rates. The disease is caused by various Candida species, with Candida albicans being the most common, although other species such as C. glabrata, C. parapsilosis, and C. tropicalis are also prevalent. IC is often associated with immunocompromised patients, those with underlying diseases, and those receiving broad-spectrum antibiotics or other immunosuppressive therapies. The burden of IC is substantial, with an estimated 63,000 infections per year in the United States, and a high mortality rate, particularly in cases of candidemia. The mortality rate for IC has remained relatively stable over the past decade, while that for invasive aspergillosis (IA) has shown a decline. Population-based surveillance studies have shown that IC is more common than other invasive fungal infections, with a high incidence in certain populations, including neonates, cancer patients, and those with diabetes. The species distribution of Candida isolates varies geographically and temporally, with C. glabrata becoming more prevalent in some regions. Antifungal susceptibility testing has revealed that some species, such as C. glabrata and C. krusei, are increasingly resistant to common antifungal agents like fluconazole. This resistance is a growing concern, as it may limit treatment options and increase mortality. The use of standardized antifungal susceptibility testing methods has improved the ability to monitor resistance patterns and guide treatment decisions. Amphotericin B remains a critical antifungal agent, although resistance to it is becoming more common in certain species. The development of resistance to amphotericin B is a significant challenge, particularly in cases involving C. glabrata. Other antifungal agents, such as triazoles, echinocandins, and 5FC, are also being used more frequently, with varying degrees of effectiveness against different Candida species. Prevention strategies, including infection control measures and prophylactic antifungal therapy, are essential in reducing the incidence and mortality of IC. The management of IC requires a multidisciplinary approach, with a focus on early diagnosis, appropriate antifungal therapy, and prevention of hospital-acquired infections. Continued research and surveillance are needed to better understand the epidemiology of IC and to develop more effective treatment strategies.